Special Report By Gardiner Harris and Alex W. Palmer — The Wire China has near-total control of the world’s antibiotic supply. Is America at risk as a result?
Special Report By Andrew Joseph Coronavirus pandemic threatens to take crushing toll on rural areas, data show
Special Report By Sharon Begley When can we let up? Health experts craft strategies to safely relax coronavirus lockdowns
Special Report By Andrew Joseph As the coronavirus spreads, a drug that once raised the world’s hopes is given a second shot
Special Report By Megan Thielking ‘A Supercenter for health’: Walmart places a big bet on cheaper, less intimidating primary care
Special Report By Natasha Gilbert ‘Dump it down the drain’: How contaminants from prescription-drug factories pollute waterways
Special Report By Eric Boodman The Medicine Hunters, Part II: Toxic weed fuels a cancer-drug gold rush — and a quandary
Special Report By Eric Boodman The Medicine Hunters, Part I: Before signing up for a trial, one patient wants to know if the drug will be affordable
Special Report By Sharon Begley Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide
Special Report By Diana Cai Chinese scientists came to the U.S. to pursue their dreams. Under tighter scrutiny, many are returning home
Special Report By Eric Boodman The vaccine whisperers: Counselors gently engage new parents before their doubts harden into certainty
Special Report By Nicholas Florko and Lev Facher How pharma, under attack from all sides, keeps winning in Washington
Special Report By Sharon Begley The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades
Special Report By Julie Appleby and Elizabeth Lucas — Kaiser Health News While addiction crisis raged, many surgeons overprescribed opioids, analysis shows
Special Report By Nicholas Florko When ‘right to try’ isn’t enough: Congress wants a single ALS patient to get a therapy never tested in humans
Special Report By Megan Thielking Celebrity-backed shows make bold pitches to health care companies — and charge big bucks. But the experiences don’t always deliver
Special Report By Andrew Joseph ‘We owe much to the Sackler family’: How gifts to a top medical school advanced the interests of Purdue Pharma
Special Report By Eric Boodman Their baby died during his nap. Then medical bureaucrats deepened the parents’ anguish
Special Report By David Armstrong — ProPublica Purdue’s Sackler embraced plan to conceal OxyContin’s strength from doctors, sealed deposition shows
Special Report By David Armstrong — ProPublica Document: Facing blame for seeding the opioid crisis, Purdue explored its next profit opportunity — treating addiction
Special Report By Matthew Herper Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Special Report By Nicholas Florko How PhRMA finally lost: the inside story of the group’s biggest lobbying failure in years
Special Report By Sharon Begley and Andrew Joseph The CRISPR shocker: How genome-editing scientist He Jiankui rose from obscurity to stun the world
Special Report By Eric Boodman These children can neither move nor speak. Clowns and engineers are trying to listen to their inner worlds
Special Report By Casey Ross Extraordinary tactics, perverse incentives: Makers of top-selling drugs hike prices in lockstep, and patients bear the cost
Special Report By Caroline Chen and Riley Wong — ProPublica Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies
Special Report By Eric Boodman An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree
Special Report By Casey Ross Artificial intelligence may not be curing cancer, but it is already changing medicine
